NEWS RELEASE
KENSINGTON, MD, Nov. 26, 2007 - Today,
Infolinx announced the adoption of its industry leading physical
records management application, Infolinx WEB, by a global
pharmaceutical corporation with roll out to Holland scheduled for
December 2007. The Leiden implementation capitalizes on the existing
Infolinx installation stateside. Additional European installations may
be forthcoming.
"We are very excited about the expandingpresence of Infolinx WEB into the Canadian and European markets" said Tim Butler, Infolinx Managing Director."Twenty years of providing contemporary software along
with reliable, and industry-leading service continues to enhance our
reputation as the industry leader for enterprise physical records management
solutions. We look forward in 2008 and beyond to an increased
international footprint, not only in the pharmaceutical industry, but in the
other major sectors as well."
In the highly regulated and competitive pharmaceutical industry, corporate records management programs have become indispensable to the continued well-being of the organization. Seeking industry-recognized compliance, pharmaceutical companies are actively seeking records management software and services to assist them in their efforts.
Under
these compliance requirements, pharmaceutical records, including
product batch and history files, research notebooks, and intellectual
property files must all now be governed by corporate policies
implemented throughout their life cycle. Inherent in these policies is
the mandatory ability to restrict, locate, track, and audit access to
all such records. Increasingly, the pharmaceutical industry is turning
to companies like Infolinx to ensure regulatory compliance and
establish programs reflecting best records management practices.
Having
provided records management consultation and software services since
1987, Infolinx has considerable experience helping pharmaceutical
providers implement strategic and scalable records management
solutions, meeting today's stringent requirements.